Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

The membrane-associated glycoprotein mucin-4 (MUC4) could block inhibitory actions of trastuzumab by directly binding with HER2, preventing interaction between the drug and its molecular target.

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

as they will be considered for the specifically engineered HER2-directed antibody drug conjugate (ADC) ENHERTU (fam-trastuzumab deruxtecan-nxki). ENHERTU was jointly developed and commercialised ...

HER2-low breast cancer falls somewhere in between. Thanks to new targeted treatments, such as a drug called trastuzumab deruxtecan, patients with HER2-low breast cancer now have more options and ...

The binding between a biosimilar and ... across the life span of the products. Stability of Her2 under 37 ℃ was determined by SDS-PAGE and ELISA Human Her2, His Tag (Cat. No. HE2-H822R ) on ...